Solutions For Unmet Diseases
PentaBind's aptamer drugs are:
-
Easy to design and don't need a complex drug conjugate linker
-
Highly selective and can actually discriminate cancer protein variants
-
'Invisible’ to the immune system and their 10x smaller size enables excellent tumour penetration
​​
The time for aptamer therapeutics is now. Key aptamer patents recently expired, the 2nd aptamer drug received FDA approval in August 2023 and PentaBind AI platform has the cracked 20 year problem of wet-laboratory aptamer design.
Unprecedented AI Models
A recent study showed PentaBind's AI models,
saved an equivalent of 38 years of manual experimental time
​
Our AI models reduce the astronomically large search space and enable the design of aptamers with ‘drug-like qualities’, a balancing of multiple design features including binding, specificity, stability etc. Traditional wet-laboratory aptamer design (SELEX) only designs for binding, only searches 1-billionth of the search space and so achieves only a 20% success rate.
​
Our models are supported by our in-house wet-laboratory data generation processes and we now have the largest dataset of its kind.
WHO WE ARE
Leading, Multidisciplinary Experts
PentaBind team have experts in aptamers, artificial intelligence, drug design, and led by serial entrepreneurs.
They have been backed by Twin Path, Entrepreneur First, KQ Labs among others.
PentaBind has been shortlisted as Best New Startup of the Year by Cancer Research Horizons.
PentaBind has been shortlisted as Deep Tech Investment of the Year by the UK Business Angels Association. This prestigious award is sponsored by the Royal Academy of Engineering
(Photo of part of the leadship team, the team size is now 10-20 people)
PentaBind
Generative Algorithms and Aptamers will unlock the next generation of therapeutics
GET IN TOUCH
Contact us for partnership or investment enquiries. For job opportunities please apply via our Careers webpage.
SUPPORTED BY
